Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #2821124

Concept 2020-01-01 to
2020-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
As at
2020-01-01
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
As at
2019-12-31
As at
2019-01-01
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
1 886 EUR
1 886 EUR
1 849 EUR
1 849 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for provisions
39,000 EUR
354,000 EUR
Other adjustments for non-cash items
23,000 EUR
0 EUR
Cash flows from (used in) operations
2 729 EUR
2 646 EUR
Income taxes paid (refund), classified as operating activities
0 EUR
0 EUR
Cash flows from (used in) operating activities
599,000 EUR
3 950 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
23,000 EUR
0 EUR
Purchase of property, plant and equipment, classified as investing activities
103,000 EUR
0 EUR
Proceeds from sales of intangible assets, classified as investing activities
0 EUR
0 EUR
Purchase of intangible assets, classified as investing activities
45,000 EUR
0 EUR
Cash flows from (used in) investing activities
125,000 EUR
0 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
1 836 EUR
939,000 EUR
Proceeds from borrowings, classified as financing activities
0 EUR
250,000 EUR
Repayments of borrowings, classified as financing activities
200,000 EUR
400,000 EUR
Cash flows from (used in) financing activities
1 547 EUR
823,000 EUR
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
823,000 EUR
3 127 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
0 EUR
0 EUR
Cash and cash equivalents
9 154 EUR
8 331 EUR
8 331 EUR
11 457 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.